3812 results for «2024»
3812 results
How to manage the complexity of multivalve disease?
17 Apr 2025 – From PCR London Valves 2024
Curious about how to manage the complexities of multivalve disease? Tiffany Patterson and Philipp Lurz share their approach to treating patients with multiple valve issues (aortic stenosis, mitral regurgitation, tricuspid regurgitation...) and discuss strategies for deciding which valve to treat first, the challenges of managing these...
What is the optimal TAVI access approach in contemporary practice?
14 May 2025 – From PCR London Valves 2024
What is the optimal TAVI access approach in today’s practice? Ole De Backer and Maarten Vanhaverbeke break down the latest evidence and trends in TAVI access. Watch this video to learn about the dominance of transfemoral access, the role of alternative routes like transcarotid and transaxillary,...
Nurses and Allied Professionals: How to safely discharge your patient post TAVI?
10 Feb 2025 – From PCR London Valves 2024
What does it take to ensure a smooth, safe, and confident discharge for TAVI patients? Sarah Carson and Gemma McCalmont share valuable insights and practical strategies. From pre-assessment planning and early mobilization to managing complications and preparing patients for recovery, this video offers essential tips for...
What do we know about bleeding risk & antithrombotic management after tricuspid valve interventions?
26 Nov 2024 – From PCR London Valves 2024
How do we navigate the thin line between bleeding risk and thrombosis in high-risk patients undergoing tricuspid valve interventions? Marianna Adamo and Fabien Praz explore the latest strategies in anticoagulation, the challenges of managing complex cases and how cutting-edge research is shaping the future of care....
Nurses and Allied Professionals: How does frailty and cognition impact patient selection for TAVI?
26 Nov 2024 – From PCR London Valves 2024
How do frailty and cognitive function shape patient selection for TAVI? Karen Wilson and Lynne Hinterbuchner discuss the essential role of screening and assessment in identifying suitable candidates, highlighting tools like the Edmonton scale and emphasizing the importance of a multidisciplinary approach to prehabilitation.
This interview was...
Insights from real-world and post-market evidence on Tricuspid TEER
26 Nov 2024 – From PCR London Valves 2024
In this video, Mirjam Wild, Tobias Kister, and Jonathan Byrne discuss real-world evidence from transcatheter edge-to-edge repair, focusing on the TriCLASP and PACE registries. These studies evaluate the PASCAL Precision system for tricuspid regurgitation and its impact on clinical practice.
This interview was filmed at PCR London...
TRISCEND II Pivotal Trial : How will TTVR impact the treatment of tricuspid regurgitation?
25 Nov 2024 – From PCR London Valves 2024
In this roundtable discussion, Marianna Adamo, Philipp Lurz, and Sam Dawkins explore the one-year outcomes of the TRISCEND II Pivotal Trial, highlighting its potential to redefine the management of severe tricuspid regurgitation. They delve into the trial’s impact on patients’ quality of life, examine its limitations,...
The Core Team shaping #PCRLV
Bioadaptor RCT 2 years: could we further improve long-term CAD outcomes vs DES?
14 May 2024 – From EuroPCR 2024
Follow this exchange between Antonio Colombo, Stefan Verheye, and Davide Capodanno as they discuss the past, present, and future of drug-eluting stents. They address the current limitations, emphasizing the issue of vessel caging, and suggest improvements, particularly highlighting the new Bioadaptor with uncaging bioresorbable elements that...
How should we manage calcific coronary disease according to the European Consensus document?
15 May 2024 – From EuroPCR 2024
Follow this exchange between James Spratt and Flavio Ribichini for insights into how the European Consensus document offers practical guidance for approaching calcified lesions, the significance of angiography findings, the critical role of intravascular imaging (IVUS or OCT), and device selection based on lesion type. Training...
Rapid learning curve to TTVR with the Cardiovalve device
15 May 2024 – From EuroPCR 2024
Explore the discussion between Rodrigo Estevez Loureiro and Georg Nickenig on treating tricuspid regurgitation with the innovative Cardiovalve replacement therapy. Learn about the unique features and properties of this low-profile valve with a dual frame, and hear Estevez Loureiro share his firsthand experience using the TTVR...
First report of an IDE pivotal study of a dedicated splitting device during TAVR
15 May 2024 – From EuroPCR 2024
Watch this interview in which Christopher Cook hosts Martin Leon to discuss pivotal study data on the ShortCut dedicated leaflet splitting device. They revisit the unmet clinical need for leaflet splitting during TAVR: transcatheter valve failures, noting that transcatheter valve failures could surpass surgical bioprosthetic valve failures...
What are the challenges for TAVI in bicuspid disease?
16 May 2024 – From EuroPCR 2024
Raj Makkar and Didier Tchétché address the complexities of bicuspid aortic valve disease, defining ideal candidates for TAVI or replacement and reviewing the NOTION-2 trial, which randomized younger, low-risk patients—including a significant number with bicuspid valves—to TAVI versus surgery. They highlight the importance of embolic protection...
How to implement the diagnosis of INOCA in everyday practice?
20 May 2025 – From EuroPCR 2025
In this exchange, Vijay Kunadian and Javier Escaned explore the real-world implementation of INOCA (Ischemia with Non-Obstructive Coronary Arteries) and ANOCA (Angina with Non-Obstructive Coronary Arteries) diagnostic pathways. Drawing on the 2024 CCS (Chronic Coronary Syndromes) guidelines, and the EAPCI consensus document, they discuss why these...
The LANDMARK RCT: key findings and relevance in clinical practice
15 May 2024 – From EuroPCR 2024
Join Patrick Serruys, Niels Van Royen, and Andreas Baumbach in a roundtable discussing the LANDMARK RCT trial, a randomized comparison of three valves aiming to validate the Myval balloon-expandable THV. Explore the trial's methodology, clinical outcomes, and findings on this new intermediate-size device, which offers adaptability...
Coronary artery stents - A comprehensive update of the chapter in The PCR Textbook
18 Jun 2024 – From EuroPCR 2024
Watch this discussion between Miklos Rohla and Stephan Windecker as they delve into the newly updated PCR Textbook chapter on stents, the first update in 6 years. This comprehensive resource includes pre-clinical and clinical findings, randomized trial evidence, and in-depth technical specs for all current stents....
Bicaval TricValve in severe tricuspid regurgitation: one-year outcomes from the Tricbicaval Registry
25 Nov 2024 – From PCR London Valves 2024
In this roundtable discussion between Angel Sanchez Recalde and Fernando Sarnago, discover the latest updates from the Tricbicaval Registry, as experts discuss the TricValve system for managing severe tricuspid regurgitation. Learn about the patient profiles included in the registry, its promising initial results, and how it...
Empire one: first-in-human study of a new transcatheter aortic valve system
25 Nov 2024 – From PCR London Valves 2024
Join this roundtable discussion with Nicola Ryan and José Antonio Baz Alonso as they delve into the Empire One trial outcomes. Learn about the IMPERIA™ delivery system for the ALLEGRA™ heart valve, its unique features, and trial results, including detailed hemodynamic findings. Hear insights on its...
The LANDMARK trial: early outcomes of a randomised non-inferiority trial comparing TAVI devices
15 May 2024 – From EuroPCR 2024
In this video, Christopher Cook interviews Patrick Serruys about the late-breaking clinical trial data from the LANDMARK RCT. Patrick Serruys begins by explaining the LANDMARK trial, which compares TAVI devices, and emphasizes the complexity of applying VARC-3 criteria. He highlights that the 30-day outcomes confirm the...
After ORBITA 2, what is the role of PCI in the contemporary management of patients with angina and coronary disease?
16 May 2024 – From EuroPCR 2024
Emanuele Barbato interviews Rasha Al-Lamee, the principal investigator of the ORBITA 2 trial, about the current role of percutaneous coronary intervention (PCI). Unlike ORBITA 1, ORBITA 2 focused on the effects of angioplasty as a monotherapy, without prior anti-angina treatment. The results showed that angioplasty improved symptoms...
